Verona Pharma Company Insiders

VRNA Stock  USD 66.81  0.54  0.81%   
About 92 percent of Verona Pharma's insiders are activelly selling. The analysis of insiders' sentiment of trading Verona Pharma PLC stock suggests that a very large number of insiders are panicking at this time. Verona Pharma employs about 209 people. The company is managed by 18 executives with a total tenure of roughly 488 years, averaging almost 27.0 years of service per executive, having 11.61 employees per reported executive.

Insider Sentiment 8

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-03-12Kathleen A RickardDisposed 79264 @ 8.35View
2024-12-06Mark W HahnDisposed 183728 @ 5.01View
2024-12-04Mark W HahnDisposed 58184 @ 5View
2024-12-02Mark W HahnDisposed 1600 @ 5View
2024-11-29Mark W HahnDisposed 98704 @ 5.01View
2024-11-27Mark W HahnDisposed 12936 @ 5View
2024-11-25Mark W HahnDisposed 1600 @ 5View
2024-11-11David ZaccardelliDisposed 2400 @ 5View
2024-11-06David R EbsworthAcquired 39360 @ 4.8View
2024-11-04Mark W HahnDisposed 80784 @ 4.39View
2024-11-01Mark W HahnDisposed 48888 @ 4.38View
2024-10-25David ZaccardelliDisposed 4800 @ 4.38View
Monitoring Verona Pharma's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Verona Pharma's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Verona Pharma's future performance. Based on our forecasts, it is anticipated that Verona will maintain a workforce of about 210 employees by April 2025.
 
Covid

Verona Pharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.2413) % which means that it has lost $0.2413 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7642) %, meaning that it created substantial loss on money invested by shareholders. Verona Pharma's management efficiency ratios could be used to measure how well Verona Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of March 22, 2025, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.38. At present, Verona Pharma's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 21.7 M, whereas Return On Tangible Assets are forecasted to decline to (0.38).
As of March 22, 2025, Common Stock Shares Outstanding is expected to decline to about 524.4 M. The current year's Net Loss is expected to grow to about (58.7 M)

Verona Pharma Workforce Comparison

Verona Pharma PLC is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 3,498. Verona Pharma holds roughly 209 in number of employees claiming about 6% of equities under Health Care industry.

Verona Pharma Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Verona Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Verona Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Verona Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
0.7778
7
9
 910,000 
 970,120 
2024-12-01
0.2778
10
36
 2,751,240 
 4,397,840 
2024-09-01
0.2857
4
14
 1,836,000 
 3,000,824 
2024-06-01
2.5
10
4
 4,560,000 
 287,160 
2024-03-01
0.3333
2
6
 260,592 
 1,289,880 
2023-12-01
1.1667
7
6
 2,389,832 
 2,219,904 
2023-09-01
0.0909
2
22
 233,976 
 1,194,680 
2023-06-01
0.7333
11
15
 887,328 
 2,086,770 
2023-03-01
0.3333
3
9
 435,800 
 1,466,336 
2022-12-01
0.05
1
20
 170,000 
 14,930,520 
2022-09-01
0.4
4
10
 13,290,104 
 2,410,976 
2022-06-01
1.5556
14
9
 2,690,104 
 1,247,312 
2022-03-01
0.5
4
8
 846,328 
 884,664 
2021-12-01
0.125
1
8
 90,104 
 1,210,768 
2021-09-01
1.1
11
10
 1,000,400 
 1,891,560 
2021-03-01
0.0909
3
33
 750,928 
 2,815,120 

Verona Pharma Notable Stakeholders

A Verona Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Verona Pharma often face trade-offs trying to please all of them. Verona Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Verona Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
David PharmDCEO PresidentProfile
Caroline DiazSenior AffairsProfile
LCSW BAG CounselProfile
Matthew CasbonMarketing SalesProfile
Peter SpargoSenior ControlsProfile
Kathleen MDChief OfficerProfile
B ASIAGeneral CounselProfile
Kavita AggarwalSenior AffairsProfile
Christopher MartinChief OfficerProfile
Nina ChurchEx DevelProfile
Tara MPHChief OfficerProfile
David ZaccardelliCEO PresProfile
Mark HahnChief OfficerProfile
Benjamin HarberCompany SecretaryProfile
Kathleen RickardChief OfficerProfile
Victoria StewartDirector CommunicationsProfile
Ostra JewellSenior ResourcesProfile
Andrew FisherGeneral CounselProfile

About Verona Pharma Management Performance

The success or failure of an entity such as Verona Pharma PLC often depends on how effective the management is. Verona Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Verona management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Verona management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.37)(0.38)
Return On Capital Employed(0.36)(0.38)
Return On Assets(0.37)(0.38)
Return On Equity(0.85)(0.89)
Please note, the presentation of Verona Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Verona Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Verona Pharma's management manipulating its earnings.

Verona Pharma Workforce Analysis

Traditionally, organizations such as Verona Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Verona Pharma within its industry.

Verona Pharma Manpower Efficiency

Return on Verona Pharma Manpower

Revenue Per Employee202.3K
Revenue Per Executive2.3M
Net Loss Per Employee829.8K
Net Loss Per Executive9.6M
Working Capital Per Employee2M
Working Capital Per Executive22.8M

Complementary Tools for Verona Stock analysis

When running Verona Pharma's price analysis, check to measure Verona Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verona Pharma is operating at the current time. Most of Verona Pharma's value examination focuses on studying past and present price action to predict the probability of Verona Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verona Pharma's price. Additionally, you may evaluate how the addition of Verona Pharma to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences